Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA ® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD)...
BW LPG Limited (“BW LPG”, the “Company”, OSE ticker code: “BWLPG.OL”), the world’s leading owner and operator of LPG vessels, announces that it has signed a contract for the construction...
- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) -...
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sportradar Group AG (NASDAQ: SRAD) Class A ordinary shares between November...
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Commvault Systems, Inc. (NASDAQ: CVLT) securities between April 29, 2025 and...
– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –
Inaugural program provides unprecedented access to Tempus’ library of de-identified multimodal data and models, scalable compute infrastructure and direct funding to catalyze clinical and technical breakthroughs...
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi ® /Minjuvi ® ) and lenalidomide in addition to R-CHOP, the current standard of care, compared with...
First PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‑altered metastatic hormone‑sensitive prostate cancer, including both BRCA and non‑BRCA alterations ...
Promising Data Further Support Continued Expansion of Ivonescimab Clinical Development in mCRC Overall Study Population Achieved ORR of 70.8% and DCR of 100.0%; Responses...
Find more press releases from the following organizations